Ding H L, Luo H J, Xu D P, Li G S
Department of Nephrology, Sichuan Provincial People's Hospital, Medical School of University of Electronic Science and Technology, Chengdu 610072, China.
Zhonghua Yi Xue Za Zhi. 2021 Mar 16;101(10):687-690. doi: 10.3760/cma.j.cn112137-20201115-03094.
Chronic kidney disease (CKD) in diabetes mellitus includes diabetic kidney disease (DKD), non-diabetic kidney disease (NDKD) or a combination of NDKD and DKD. The clinical and renal pathological manifestations of DKD in type 1 diabetes are different from those in type 2 diabetes. Renal biopsy histopathology is the gold standard for distinguishing DKD from NDKD. However, based on the same pathological diagnosis, DKD patients may still have different disease progression and prognosis due to individual differences in molecular biological mechanisms. Metabonomics, proteomics, transcriptomics and artificial intelligence offer hope for biomarkers to diagnose and predict the progress of DKD.
糖尿病中的慢性肾脏病（CKD）包括糖尿病肾病（DKD）、非糖尿病肾病（NDKD）或NDKD与DKD的组合。1型糖尿病中DKD的临床和肾脏病理表现与2型糖尿病不同。肾活检组织病理学是区分DKD与NDKD的金标准。然而，基于相同的病理诊断，由于分子生物学机制的个体差异，DKD患者仍可能有不同的疾病进展和预后。代谢组学、蛋白质组学、转录组学和人工智能为诊断和预测DKD的进展提供了寻找生物标志物的希望。
